Volume 13, Number 9—September 2007
Dispatch
Parenteral Transmission of the Novel Human Parvovirus PARV4
Table 1
Participant category (no.) | M/F | Age at death, y (range)† | Year of death (range)† | Mean CD4/μL (range)† | AIDS? | B19 positive, no. (%) | PARV4 positive, no. (%) |
---|---|---|---|---|---|---|---|
HIV+ IDU, AIDS‡ (13) | 10/3 | 35 (2–48) | 1995 (1991–1998) | 44 (1–137) | Y | 6 (46) | 11 (85) |
HIV+ IDU, pre-AIDS‡ (11) | 7/4 | 33 (29–40) | 1996 (1992–1998) | 268 (167–496) | N | 6 (55) | 6 (55) |
HIV+ MSM (13) | 13/0 | 39 (28–49) | 1993 (1990–1996) | 25 (1–160) | Y | 7 (54) | 0 |
HIV– IDU (12) | 10/2 | 35 (24–49) | 1999 (1992–2005) | ND | NA | 8 (67) | 1 (8) |
Hemophilia (2) | 2/0 | 22, 26 | 1994, 1995 | 0 | Y | 0 | 1 (50) |
Low-risk control§ (8) | 3/5 | 54 (28–89) | All 2005 | ND | NA | 8 (100) | 0 |
*IDU, injection drug user; M, male; F, female; Y, yes; N, no; MSM, men who had sex with men; ND, not done; NA, not applicable.
†Values are means (ranges) or individual values for those with hemophilia.
‡These study groups overlap with the previously analyzed HIV-positive group (8), restricted to those in whom parenteral risk factors for infection have been identified.
§Previously described in (8).
References
- Jones MS, Kapoor A, Lukashov VV, Simmonds P, Hecht F, Delwart E. New DNA viruses identified in patients with acute viral infection syndrome. J Virol. 2005;79:8230–6. DOIPubMedGoogle Scholar
- Fryer JF, Kapoor A, Minor PD, Delwart E, Baylis SA. Novel parvovirus and related variant in human plasma. Emerg Infect Dis. 2006;12:151–4.PubMedGoogle Scholar
- Fryer JF, Delwart E, Hecht FM, Bernardin F, Jones MS, Shah N, Frequent detection of the parvoviruses, PARV4 and PARV5, in plasma from blood donors and symptomatic individuals. Transfusion. 2007;47:1054–61. DOIPubMedGoogle Scholar
- Fryer JF, Lucas SB, Padley D, Baylis SA. Parvoviruses PARV4/5 in hepatitis C virus–infected patient. Emerg Infect Dis. 2007;13:175–6. DOIPubMedGoogle Scholar
- Soderlund-Venermo M, Hokynar K, Nieminen J, Rautakorpi H, Hedman K. Persistence of human parvovirus B19 in human tissues. Pathol Biol (Paris). 2002;50:307–16. DOIPubMedGoogle Scholar
- Norja P, Hokynar K, Aaltonen LM, Chen R, Ranki A, Partio EK, Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue. Proc Natl Acad Sci U S A. 2006;103:7450–3. DOIPubMedGoogle Scholar
- Isa A, Kasprowicz V, Norbeck O, Loughry A, Jeffery K, Broliden K, Prolonged activation of virus-specific CD8+T cells after acute B19 infection. PLoS Med. 2005;2:e343. DOIPubMedGoogle Scholar
- Manning A, Willey SJ, Bell JE, Simmonds P. Tissue distribution, persistence and molecular epidemiology of parvovirus B19 and novel human parvoviruses, PARV4 and human bocavirus. J Infect Dis. 2007;195:1345–52. DOIPubMedGoogle Scholar
- Vyse AJ, Andrews NJ, Hesketh LM, Pebody R. The burden of parvovirus B19 infection in women of childbearing age in England and Wales. Epidemiol Infect. 2007; 1–9.
- Hagan H, Des J. HIV and HCV infection among injecting drug users. Mt Sinai J Med. 2000;67:423–8.PubMedGoogle Scholar
- Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Andersson B. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci U S A. 2005;102:12891–6. DOIPubMedGoogle Scholar
Page created: July 01, 2010
Page updated: July 01, 2010
Page reviewed: July 01, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.